U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H23NO6
Molecular Weight 325.3569
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MONOCROTALINE

SMILES

[H][C@@]12[C@H]3CCN1CC=C2COC(=O)[C@](C)(O)[C@](C)(O)[C@@H](C)C(=O)O3

InChI

InChIKey=QVCMHGGNRFRMAD-XFGHUUIASA-N
InChI=1S/C16H23NO6/c1-9-13(18)23-11-5-7-17-6-4-10(12(11)17)8-22-14(19)16(3,21)15(9,2)20/h4,9,11-12,20-21H,5-8H2,1-3H3/t9-,11+,12+,15+,16-/m0/s1

HIDE SMILES / InChI

Molecular Formula C16H23NO6
Molecular Weight 325.3569
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Monocrotaline is an 11-membered macrocyclic pyrrolizidine alkaloid derived from the seeds of the Crotalaria spectabilis plant. Monocrotaline is activated to the reactive pyrrole metabolite dehydromonocrotaline in the liver, a reaction that is highly dependent on cytochrome P-450 (CYP3A4). Monocrotaline induces a syndrome characterized, among other manifestations, by pulmonary hypertension, pulmonary mononuclear vasculitis (acute necrotizing pulmonary arteritis in about one-third of the animals), and right ventricular hypertrophy. Monocrotaline is widely used to model pulmonary arterial hypertension in rodents. Monocrotaline aggregates on and activates the extracellular calcium-sensing receptor (CaSR) of pulmonary artery endothelial cells to trigger endothelial damage and, ultimately, induces pulmonary hypertension.

Originator

Curator's Comment: reference retrieved from http://pubs.acs.org/doi/abs/10.1021/ja01265a073

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
PubMed

PubMed

TitleDatePubMed
Genomic approaches to research in pulmonary hypertension.
2001
Role of endothelin-1 in lung disease.
2001
[Monocrotaline induce pulmonary hypertension in animal models].
2001 Apr-Jun
Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles.
2001 Aug 15
40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats.
2001 Feb
Development of a (32)P-postlabeling/HPLC method for detection of dehydroretronecine-derived DNA adducts in vivo and in vitro.
2001 Jan
Micronucleus formation in human lymphocytes and in the metabolically competent human hepatoma cell line Hep-G2: results with 15 naturally occurring substances.
2001 Jan-Feb
All-trans retinoic acid in pulmonary vascular structural remodeling in rats with pulmonary hypertension induced by monocrotaline.
2001 May
Stage-dependent activation of cell cycle and apoptosis mechanisms in the right ventricle by pressure overload.
2002 Apr 24
Pyrrolizidine alkaloid clivorine inhibits human normal liver L-02 cells growth and activates p38 mitogen-activated protein kinase in L-02 cells.
2002 Dec
Effects of diesel exhaust enriched concentrated PM2.5 in ozone preexposed or monocrotaline-treated rats.
2002 Jul
The temporal relationship between bacterial lipopolysaccharide and monocrotaline exposures influences toxicity: shift in response from hepatotoxicity to nitric oxide-dependent lethality.
2002 Jul 26
Dietary fish oil protects against lung and liver inflammation and fibrosis in monocrotaline treated rats.
2002 Jun 14
L-Carnitine: a potential treatment for blocking apoptosis and preventing skeletal muscle myopathy in heart failure.
2002 Sep
Gender differences in pulmonary arterial reactivity to dilatory agonists in pulmonary hypertension.
2003
DA-8159, a potent cGMP phosphodiesterase inhibitor, attenuates monocrotaline-induced pulmonary hypertension in rats.
2003 Aug
Liver inflammation during monocrotaline hepatotoxicity.
2003 Aug 28
Taste receptors for pyrrolizidine alkaloids in a monophagous caterpillar.
2003 Jul
Effects of monocrotaline pyrrole and thrombin on pulmonary endothelial cell junction and matrix adhesion proteins.
2003 Mar 3
Granulocyte colony-stimulating factor enhances alpha-naphthylthiourea-induced pulmonary hypertension.
2003 May
Rhythmical contractions in pulmonary arteries of monocrotaline-induced pulmonary hypertensive rats.
2003 Nov
Basement membrane and matrix metalloproteinases in monocrotaline-induced liver injury.
2003 Nov
Identification of DNA adducts derived from riddelliine, a carcinogenic pyrrolizidine alkaloid.
2003 Sep
Sinusoidal obstruction syndrome (veno-occlusive disease) in the rat is prevented by matrix metalloproteinase inhibition.
2003 Sep
Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells.
2003 Sep 30
Beneficial effects of GH/IGF-1 on skeletal muscle atrophy and function in experimental heart failure.
2004 Jan
Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats.
2004 Jan 1
Patents

Sample Use Guides

Rodents: 45-300 mg/kg
Route of Administration: Parenteral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 19:13:27 GMT 2023
Edited
by admin
on Fri Dec 15 19:13:27 GMT 2023
Record UNII
73077K8HYV
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MONOCROTALINE
HSDB   MI  
Common Name English
NCI-C56462
Code English
CROTALINE
Common Name English
(-)-MONOCROTALINE
Common Name English
2H-(1,6)DIOXACYCLOUNDECINO(2,3,4-GH)PYRROLIZINE-2,6(3H)-DIONE, 4,5,8,10,12,13,13A,13B-OCTAHYDRO-4,5-DIHYDROXY-3,4,5-TRIMETHYL-, (3R,4R,5R,13AR,13BR)-
Common Name English
20-NORCROTALANAN-11,15-DIONE, 14,19-DIHYDRO-12,13-DIHYDROXY-, (13.ALPHA.,14.ALPHA.)-
Common Name English
MONOCROTALINE [MI]
Common Name English
2H-(1,6)DIOXACYCLOUNDECINO(2,3,4-GH)PYRROLIZINE-2,6(3H)-DIONE, 4,5,8,10,12,13,13A,13B-OCTAHYDRO-4,5-DIHYDROXY-3,4,5-TRIMETHYL-, (3R-(3R*,4R*,5R*,13AR*,13BR*))-
Common Name English
MONOCROTALINE [HSDB]
Common Name English
MONOCROTALINE [IARC]
Common Name English
NSC-28693
Code English
Code System Code Type Description
EPA CompTox
DTXSID9020902
Created by admin on Fri Dec 15 19:13:27 GMT 2023 , Edited by admin on Fri Dec 15 19:13:27 GMT 2023
PRIMARY
MESH
D016686
Created by admin on Fri Dec 15 19:13:27 GMT 2023 , Edited by admin on Fri Dec 15 19:13:27 GMT 2023
PRIMARY
PUBCHEM
9415
Created by admin on Fri Dec 15 19:13:27 GMT 2023 , Edited by admin on Fri Dec 15 19:13:27 GMT 2023
PRIMARY
FDA UNII
73077K8HYV
Created by admin on Fri Dec 15 19:13:27 GMT 2023 , Edited by admin on Fri Dec 15 19:13:27 GMT 2023
PRIMARY
NSC
28693
Created by admin on Fri Dec 15 19:13:27 GMT 2023 , Edited by admin on Fri Dec 15 19:13:27 GMT 2023
PRIMARY
HSDB
3513
Created by admin on Fri Dec 15 19:13:27 GMT 2023 , Edited by admin on Fri Dec 15 19:13:27 GMT 2023
PRIMARY
CHEBI
6980
Created by admin on Fri Dec 15 19:13:27 GMT 2023 , Edited by admin on Fri Dec 15 19:13:27 GMT 2023
PRIMARY
CAS
315-22-0
Created by admin on Fri Dec 15 19:13:27 GMT 2023 , Edited by admin on Fri Dec 15 19:13:27 GMT 2023
PRIMARY
MERCK INDEX
m7606
Created by admin on Fri Dec 15 19:13:27 GMT 2023 , Edited by admin on Fri Dec 15 19:13:27 GMT 2023
PRIMARY Merck Index
Related Record Type Details
METABOLITE -> PARENT
MAJOR